（以下无正文） 关于深圳市亚辉龙生物科技股份有限公司 控股股东、实际控制人：胡鹍辉 股票交易严重异常波动有关事项问询函的回函 2024 年 11 月 7 日 致：深圳市亚辉龙生物科技股份有限公司 本人已收到贵司发来的《关于深圳市亚辉龙生物科技股份有限公司股票交易 严重异常波动有关事项的问询函》，经认真自查，现就有关情况回复如下： 截至本函签署日，作为公司的控股股东及实际控制人，不存在影响上市公司 股票交易严重异常波动的重大事项；不存在应披露而未披露的重大事项，包括但 不限于重大资产重组、股份发行、债务重组、业务重组、资产剥离和资产注入等 重大事项。 本人在股票交易严重异常波动期间不存在买卖公司股票的情况。 ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-069 深圳市亚辉龙生物科技股份有限公司 股票交易严重异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）股票交易连续 30 个交易日内（2024 年 9 月 20 日至 2024 年 11 月 7 日）收盘价格跌幅偏离值累计达到 70% 以上，根据《上海证券交易所科创板股票上市规则》（以下简称《科创板上市规则》） 《上海证券交易所交易规则》《上海证券交易所科创板股票异常交易实时监控细则》的 有关规定，属于股票交易严重异常波动情形。 经公司自查，并发函问询控股股东、实际控制人，截至 2024 年 11 月 7 日，无 应披露而未披露的重大事项。 截至 2024 年 11 月 7 日，公司收盘价为 18.26 元/股。根据中证指数有限公司发 布的数据，截至 2024 年 11 月 7 日，公司最新滚动市盈率为 36.08 倍，公司所处的医药 制造业最近一个月平均滚动市盈率为 27.03 ...

Investment Rating - Outperform rating with a target price range of 21.23-23.42 RMB, implying a 15.9-27.9% upside from the current price [1][3] Core Views - The company is a leading domestic brand in chemiluminescence, with a complete product portfolio covering high, medium, and low-end models and intelligent assembly lines [1] - The chemiluminescence business is the core growth driver, with revenue growing from 140 million RMB in 2018 to 1.17 billion RMB in 2023, a CAGR of over 50% [1] - The company has a strong presence in key areas such as autoimmune diseases, reproductive health, diabetes, infectious diseases, liver diseases, and cardiovascular diseases [1] - The company's strategy of "specialized entry, routine expansion" has been effective, with routine diagnostic reagent revenue growing 50.20% YoY in 2023 and 52.48% YoY in H1 2024 [1] - The company is expanding internationally, with overseas non-COVID business revenue growing rapidly, driven by partnerships such as with Japan's MBL [1] Industry Overview - The global in-vitro diagnostics (IVD) market is expected to reach 106.5 billion USD in 2023, with a CAGR of 3.8% from 2023-2028 [21] - The Chinese IVD market is expected to reach 120 billion RMB in 2023, with immunodiagnostics being the largest segment at 37.5 billion RMB, growing 13% YoY [21][23] - Chemiluminescence is the mainstream advanced technology in immunodiagnostics due to its high sensitivity, wide linear range, and rapid clinical application [23] - The domestic autoimmune diagnostics market is estimated at 1.5-2 billion RMB, with significant growth potential as autoimmune diseases become more recognized and treated [1][27] Company Performance and Strategy - The company's revenue grew from 722 million RMB in 2018 to 1.676 billion RMB in 2023, with a CAGR of 18.3% [17] - Non-COVID self-produced business revenue grew from 246 million RMB in 2018 to 1.326 billion RMB in 2023, a CAGR of 40.1% [17] - The company has a comprehensive product menu with 176 chemiluminescence diagnostic items, leading the industry in autoimmune diagnostics with 60 items [33] - The company has achieved wide coverage in high-grade hospitals, with over 35% of its total installations in Tier 3 and above hospitals [35] - The company is expanding its product line with new technologies such as multi-detection and microfluidics, and aims to increase self-produced raw material rate to over 80% in the next 3-5 years [38] Financial Projections - Revenue is projected to be 2.044 billion RMB in 2024, 2.502 billion RMB in 2025, and 3.078 billion RMB in 2026, with YoY growth rates of -0.5%, 22.4%, and 23.1% respectively [1] - Net profit is projected to be 381 million RMB in 2024, 513 million RMB in 2025, and 667 million RMB in 2026, with YoY growth rates of 7.4%, 34.5%, and 30.0% respectively [1] - EPS is projected to be 0.67 RMB in 2024, 0.90 RMB in 2025, and 1.17 RMB in 2026, with a current PE ratio of 27x, 20x, and 16x respectively [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2024-067 深圳市亚辉龙生物科技股份有限公司 关于 2023 年限制性股票激励计划第一个归属期 归属结果暨股份上市公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为 991,500 股。 本次股票上市流通总数为 991,500 股。 本次股票上市流通日期为 2024 年 11 月 7 日。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）收到中国证券登记结 算有限责任公司上海分公司于 2024 年 11 月 1 日出具的《证券变更登记证明》，公 司完成了 2023 年限制性股票激励计划（以下简称"本激励计划"）第一个归属期的 股份登记工作。现将有关情况公告如下： 一、本次限制性股票归属的决策程序及相关信息披露 1、2023 年 9 月 14 日，公司召开第三届董事会第十六次会议，审议通过了《关 于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于公司<2023 年 ...

Summary of Conference Call Records Company and Industry Overview - The conference call discusses the performance and strategic direction of a company in the chemical luminescence diagnostics industry, specifically focusing on its recent quarterly results and future outlook. Key Points and Arguments Financial Performance - For the first three quarters of 2024, the company reported total revenue of **1.394 billion** (13.94亿), a year-on-year decline of **9.78%** [2] - Non-COVID related revenue was **1.142 billion** (11.42亿), showing a growth of **24.4%** year-on-year [2] - The company’s gross margin for the first three quarters was **63.36%**, an increase of **10 percentage points** from the previous year [3] - The revenue from the chemical luminescence business was **1.037 billion** (10.37亿), a year-on-year increase of **29.15%** [4] Business Segments - Domestic non-COVID related revenue was **993 million** (9.93亿), up **22%** year-on-year, while international revenue was **149 million** (1.49亿), up **41.34%** [2] - The company’s sales expenses increased by **6.47%**, while management expenses remained stable with a growth of **0.37%** [4] - R&D expenses were **229 million** (2.29亿), maintaining a rate of **16%** of total revenue [4] Market Dynamics - The company is facing inventory challenges due to rapid growth and is actively working on inventory reduction strategies [1][10] - The inventory turnover period is currently around **4.8 months**, with a target to normalize to **2-3 months** [11] - The company is committed to cost reduction and efficiency improvements, particularly in raw material sourcing [10][14] Future Outlook - The company aims for its chemical luminescence business to grow at a rate of **30%** over the next three to five years [15][17] - The company is expanding its market presence internationally, particularly in regions like the Middle East and South Asia [18] - The introduction of new products and enhancements in service delivery are expected to drive future growth [24] Strategic Initiatives - The company has signed partnerships for laboratory automation systems to enhance operational efficiency [6] - A new training service center in Cairo has been established to support local service capabilities [7] - The company is focusing on increasing its market share in the self-testing diagnostics segment, which is projected to grow significantly [35][36] Regulatory Environment - The upcoming implementation of centralized procurement policies is expected to impact pricing and market dynamics, but the company views this as an opportunity for growth in market share [26][28] - The company is preparing for the second round of centralized procurement, which may lead to increased competition but also greater opportunities for domestic products [26] Challenges and Risks - The company acknowledges the impact of DRGs (Diagnosis-Related Groups) on testing volumes, which may affect revenue in the short term [30][32] - There is a recognition of the need to adapt to changing market conditions and regulatory frameworks to maintain competitive advantage [32][40] Additional Important Content - The company has achieved significant milestones in product development and market penetration, including the launch of new diagnostic solutions and enhancements in existing product lines [39] - The focus on academic collaborations and partnerships is seen as a key strategy for driving innovation and expanding market reach [7][18] This summary encapsulates the essential insights from the conference call, highlighting the company's financial performance, strategic initiatives, market dynamics, and future outlook within the chemical luminescence diagnostics industry.

Investment Rating - The investment rating for the company is "Buy" [4][8] Core Views - The company reported a revenue of 1.39 billion yuan for the first three quarters of 2024, a year-on-year decrease of 9.8%, with a net profit attributable to shareholders of 219 million yuan, down 23.3% [1] - The company's self-produced non-COVID business revenue reached 1.14 billion yuan, showing a growth of 24.4%, with self-produced luminescence revenue at 1.04 billion yuan, up 29.2%, and overseas luminescence revenue at 135 million yuan, increasing by 45.7% [1] - The company added 1,727 units of chemical luminescence instruments in Q1-3 2024, with domestic installations accounting for 995 units, of which 600-speed machines made up 46.43% [1] - The overall gross margin for Q3 2024 was 66.84%, showing significant improvement compared to previous quarters [1] Financial Data and Valuation - The company is projected to have an EPS of 0.73, 0.93, and 1.19 yuan for 2024, 2025, and 2026 respectively, with corresponding P/E ratios of 25, 19, and 15 [2][3] - Revenue for 2024 is estimated at 2.22 billion yuan, with a growth rate of 8%, followed by 2.79 billion yuan in 2025 and 3.42 billion yuan in 2026, reflecting growth rates of 26% and 23% respectively [3] - The net profit for 2024 is expected to be 418 million yuan, with a growth rate of 18%, increasing to 531 million yuan in 2025 and 679 million yuan in 2026, with growth rates of 27% and 28% respectively [3]

[Table_StockNameRptType] 亚辉龙（688575） | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------|----------------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

深圳市亚辉龙生物科技股份有限公司 投资者关系活动记录表 （2024 年 10 月 30 日） 股票简称：亚辉龙 股票代码：688575 | --- | --- | --- | |--------------|-------------------------------|------------------------------| | | £ 特定对象调研 | £ 分析师会议 | | 投资者关系活 | £ 媒体采访 | R 业绩说明会 | | 动类别 | £ 新闻发布会 | £ 路演活动 | | | £ 现场参观 | £ 其他： | | 参与单位名称 | 共 116 家机构合计 | 143 人（详见附件与会清单） | | 时间 | 2024 年 10 月 30 日 | | | 地点 | 线上会议 | | | 公司接待人员 | 董事长：胡鹍辉 | | | 姓名 | 董事/财务总监：廖立生 | | | | 营销总部副总经理/国内营销轮值 | CEO ：于秋萍 | | | 董事会秘书：王鸣阳 | | | | 学术总监：王茗 | | | --- | --- | |--------------|----------- ...

证券代码：688575 证券简称：亚辉龙 公告编号：2024-065 深圳市亚辉龙生物科技股份有限公司 第三届董事会第二十七次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 深圳市亚辉龙生物科技股份有限公司（以下简称"公司"）第三届董事会第二十七 次会议（以下简称"本次会议"）于 2024 年 10 月 28 日以现场加通讯方式召开，会议 应到董事 7 人，实到董事 7 人，出席董事占应出席人数的 100%。本次会议的召集、 召开程序符合《公司章程》和有关法律、法规的要求。经与会董事审议和表决，会议 形成如下决议： 表决结果：7 票同意；0 票反对；0 票弃权。 本议案已经审计委员会审议通过，并同意提交董事会审议。 二、审议通过《关于变更注册资本暨修订<公司章程>的议案》 具体内容详见同日在上海证券交易所网站（www.sse.com.cn）上披露的《深圳市 亚辉龙生物科技股份有限公司关于变更注册资本暨修订<公司章程>的公告》（公告编 号：2024-066） 表决结果：7 票同意；0 票反对；0 票弃权。 根据 ...